{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:36:03Z","timestamp":1794623763258,"version":"4.9.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,7]]},"DOI":"10.7759\/cureus.35871","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T15:02:41Z","timestamp":1678201361000},"source":"Crossref","is-referenced-by-count":3,"title":["Multiple Autoimmune Complications After a Single Dose of Pembrolizumab"],"prefix":"10.7759","author":[{"given":"Hardeep S","family":"Ahdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufyan","family":"Abdulmujeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Nabrinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino M","year":"2018","unstructured":"Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018, 6:e00355. 10.1002\/rcr2.355","journal-title":"Respirol Case Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan KK","year":"2020","unstructured":"Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. 2020, 369:m736. 10.1136\/bmj.m736","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?","volume":"11","author":"Franzin R","year":"2020","unstructured":"Franzin R, Netti GS, Spadaccino F, et al.. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?. Front Immunol. 2020, 11:574271. 10.3389\/fimmu.2020.574271","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220921543","article-title":"Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab","volume":"27","author":"Kethireddy N","year":"2021","unstructured":"Kethireddy N, Thomas S, Bindal P, Shukla P, Hegde U. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab. J Oncol Pharm Pract. 2021, 27:207-11. 10.1177\/1078155220921543","journal-title":"J Oncol Pharm Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system","volume":"11","author":"Dalakas MC","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system. Ther Adv Neurol Disord. 2018, 11:1756286418799864. 10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao JC","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, et al.. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017, 74:1216-22. 10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P4.2-007","article-title":"Pembrolizumab-induced myasthenia gravis (P4.2-007)","volume":"92","author":"Algaeed M","year":"2019","unstructured":"Algaeed M, Mukharesh L, Heinzelmann M, Kaminski HJ. Pembrolizumab-induced myasthenia gravis (P4.2-007). Neurology. 2019, 92:","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15174","article-title":"Pembrolizumab-associated seronegative myasthenia gravis in a patient with metastatic renal cell carcinoma","volume":"13","author":"Pandya SK","year":"2021","unstructured":"Pandya SK, Ulrickson M, Dong J, Willen R, Pandya A. Pembrolizumab-associated seronegative myasthenia gravis in a patient with metastatic renal cell carcinoma. Cureus. 2021, 13:e15174. 10.7759\/cureus.15174","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March KL","year":"2018","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2018, 24:146-9. 10.1177\/1078155216687389","journal-title":"J Oncol Pharm Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253070","article-title":"Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy","volume":"16","author":"Cunningham M","year":"2021","unstructured":"Cunningham M, Iafolla M, Kanjanapan Y, et al.. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS One. 2021, 16:e0253070. 10.1371\/journal.pone.0253070","journal-title":"PLoS One"},{"key":"ref12","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. (2022). Accessed: 11\/23\/2022: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548050\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.003","article-title":"Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab","volume":"121","author":"Song P","year":"2019","unstructured":"Song P, Zhang L. Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. Eur J Cancer. 2019, 121:4-6. 10.1016\/j.ejca.2019.08.003","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.073","article-title":"Two cases of immune thrombocytopenia associated with pembrolizumab","volume":"54","author":"Le Roy A","year":"2016","unstructured":"Le Roy A, Kempf E, Ackermann F, et al.. Two cases of immune thrombocytopenia associated with pembrolizumab. Eur J Cancer. 2016, 54:172-4. 10.1016\/j.ejca.2015.10.073","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11852","article-title":"Severe thrombocytopenia associated with pembrolizumab in patients with non-small cell lung cancer (NSCLC): a case report and literature review","volume":"34","author":"Mouri A","year":"2020","unstructured":"Mouri A, Kaira K, Shiono A, Miura YU, Kagamu H. Severe thrombocytopenia associated with pembrolizumab in patients with non-small cell lung cancer (NSCLC): a case report and literature review. In Vivo. 2020, 34:877-80. 10.21873\/invivo.11852","journal-title":"In Vivo"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/141433-multiple-autoimmune-complications-after-a-single-dose-of-pembrolizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:51:50Z","timestamp":1707490310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/141433-multiple-autoimmune-complications-after-a-single-dose-of-pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.35871","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}